(Q29619501)

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=9250266

30 April 2017

0 references

2

Guyatt GH

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=9250266

30 April 2017

author name string

Bucher HC

series ordinal

1

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=9250266

30 April 2017

Griffith LE

series ordinal

3

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=9250266

30 April 2017

Walter SD

series ordinal

4

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=9250266

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=9250266

30 April 2017

language of work or name

1 reference

30 April 2017

publication date

June 1997

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=9250266

Journal of Clinical Epidemiology

30 April 2017

published in

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=9250266

30 April 2017

volume

50

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=9250266

30 April 2017

issue

6

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=9250266

30 April 2017

page(s)

683-91

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=9250266

The comparative efficacy and toxicity of second-line drugs in rheumatoid arthritis results of two metaanalyses

30 April 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0895-4356%2897%2900049-8

7 January 2021

Combined effect size: comment on the metaanalysis of second-line drugs in rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS0895-4356%2897%2900049-8

7 January 2021

Meta-analysis of prophylactic treatments against Pneumocystis carinii pneumonia and toxoplasma encephalitis in HIV-infected patients

1 reference

https://api.crossref.org/works/10.1016%2FS0895-4356%2897%2900049-8

7 January 2021

A controlled trial of trimethoprim-sulfamethoxazole or aerosolized pentamidine for secondary prophylaxis of Pneumocystis carinii pneumonia in patients with the acquired immunodeficiency syndrome. AIDS Clinical Trials Group Protocol 021

1 reference

https://api.crossref.org/works/10.1016%2FS0895-4356%2897%2900049-8

7 January 2021

A controlled trial of aerosolized pentamidine or trimethoprim-sulfamethoxazole as primary prophylaxis against Pneumocystis carinii pneumonia in patients with human immunodeficiency virus infection. The Dutch AIDS Treatment Group

1 reference

https://api.crossref.org/works/10.1016%2FS0895-4356%2897%2900049-8

7 January 2021

Randomized study of sulfamethoxazole-trimethoprim versus aerosolized pentamidine for secondary prophylaxis of Pneumocystis carinii pneumonia in patients with AIDS.

1 reference

https://api.crossref.org/works/10.1016%2FS0895-4356%2897%2900049-8

7 January 2021

Patient tolerance of nebulized pentamidine or cotrimoxazole as secondary prophylaxis for Pneumocystis carinii pneumonia

1 reference

https://api.crossref.org/works/10.1016%2FS0895-4356%2897%2900049-8

7 January 2021

Risks and benefits of aerosolized pentamidine and cotrimoxazole in primary prophylaxis of Pneumocystis carinii pneumonia in HIV-1-infected patients: a two-year Italian multicentric randomized controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0895-4356%2897%2900049-8

7 January 2021

Dapsone-pyrimethamine compared with aerosolized pentamidine as primary prophylaxis against Pneumocystis carinii pneumonia and toxoplasmosis in HIV infection. The PRIO Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0895-4356%2897%2900049-8

7 January 2021

Once-weekly administration of dapsone/pyrimethamine vs. aerosolized pentamidine as combined prophylaxis for Pneumocystis carinii pneumonia and toxoplasmic encephalitis in human immunodeficiency virus-infected patients

1 reference

https://api.crossref.org/works/10.1016%2FS0895-4356%2897%2900049-8

7 January 2021

Oral dapsone versus nebulized pentamidine for Pneumocystis carinii pneumonia prophylaxis

1 reference

https://api.crossref.org/works/10.1016%2FS0895-4356%2897%2900049-8

7 January 2021

Randomized trial of dapsone and aerosolized pentamidine for the prophylaxis of Pneumocystis carinii pneumonia and toxoplasmic encephalitis

1 reference

https://api.crossref.org/works/10.1016%2FS0895-4356%2897%2900049-8

7 January 2021

Thrice-weekly cotrimoxazole is better than weekly dapsone-pyrimethamine for the primary prevention of Pneumocystis carinii pneumonia in HIV-infected patients.

1 reference

https://api.crossref.org/works/10.1016%2FS0895-4356%2897%2900049-8

7 January 2021

Intermittent trimethoprim-sulfamethoxazole compared with dapsone-pyrimethamine for the simultaneous primary prophylaxis of Pneumocystis pneumonia and toxoplasmosis in patients infected with HIV

1 reference

https://api.crossref.org/works/10.1016%2FS0895-4356%2897%2900049-8

7 January 2021

A randomized trial of three antipneumocystis agents in patients with advanced human immunodeficiency virus infection. NIAID AIDS Clinical Trials Group

1 reference

https://api.crossref.org/works/10.1016%2FS0895-4356%2897%2900049-8

7 January 2021

Failure of low-dose dapsone-pyrimethamine in primary prophylaxis of Pneumocystis carinii pneumonia

1 reference

https://api.crossref.org/works/10.1016%2FS0895-4356%2897%2900049-8

7 January 2021

Four different regimens for prevention of Pneumocystis carinii pneumonia and toxoplasma encephalitis in HIV-infected patients

1 reference

https://api.crossref.org/works/10.1016%2FS0895-4356%2897%2900049-8

7 January 2021

A method for assessing the quality of a randomized control trial

1 reference

https://api.crossref.org/works/10.1016%2FS0895-4356%2897%2900049-8

7 January 2021

Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials

1 reference

https://api.crossref.org/works/10.1016%2FS0895-4356%2897%2900049-8

7 January 2021

10.1016/S0895-4356(97)00049-8

Identifiers

DOI

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/nfxki2gw2rbgnbnhc4xdbwdcky

30 July 2022

mapped directly with Wikidata item

Fatcat ID

release_nfxki2gw2rbgnbnhc4xdbwdcky

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/nfxki2gw2rbgnbnhc4xdbwdcky

30 July 2022

mapped directly with Wikidata item

OpenCitations bibliographic resource ID

1016149

1 reference

Consolidated OpenCitations Corpus – April 2017

OpenCitations bibliographic resource ID

1016149

PubMed publication ID

1 reference

https://api.fatcat.wiki/v0/release/nfxki2gw2rbgnbnhc4xdbwdcky

30 July 2022